Uniqure N.V. (QURE)

$47.51 -1.59 (-3.24%)
Market Cap 3.00B
Revenue (ttm) 16.10M
Net Income (ttm) -198.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,235.84%
Debt to Equity Ratio 0.33
Volume 3,155,900
Avg Vol 2,310,678
Day's Range N/A - N/A
Shares Out 63.07M
Stochastic %K 88%
Beta 0.98
Analysts Strong Sell
Price Target $65.10

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 20 240 6000
Address:
Paasheuvelweg 25, Amsterdam, Netherlands
Thinkingman91
Thinkingman91 Jun. 29 at 2:00 PM
$CLPT $QURE $SRRK I’ve given you 3 since December and all went 50% or more. Im a chart specialist focusing on returns 🫡
1 · Reply
free2dream
free2dream Jun. 29 at 1:45 PM
$SPY LOAD UP ON $SRPT THE REAL SQUEEZE IS COMING 25% short float, pathetic 1.7B market cap while $QURE is at $3.3B . SAREPTA WIL GAP UP TO $60S easily
0 · Reply
free2dream
free2dream Jun. 29 at 1:36 PM
$SRPT ANALYST MORONS WAKE THE FXCK UP ! $QURE IS WORTH 2X SAREPTA ? YOU MUST BE JOKING
0 · Reply
victorgn
victorgn Jun. 29 at 1:15 PM
$QURE pops on open $52
0 · Reply
Benalish
Benalish Jun. 28 at 1:14 AM
$OMER Good time to be buying back conv debt. EU doesn’t like lack of placebo - just like $QURE in the USA. As I posted below, they have a better chance of approval with the appeal than they ever did with the initial due to the inclusion of real life experts who use Yart in the clinic. If I had known how this goes it would have been easy to anticipate. Good timing by $OMER to buy back conv during this manufactured pullback. Shorts knew it just like they knew $REPL was gonna get denied with Makary and Prasad at the FDA. Now $NVO heading back to $60 - they will probably consider cranking up the testing or maybe even a buyout at $20. Lots of biotech deals on the way with prices heating up !
1 · Reply
Evagaminska
Evagaminska Jun. 26 at 9:31 PM
$CAPR FDA still has clowns working there I guess if they schedule ADCOM but company isn’t aware. Prasad by issuing CRL without ADCOM that he himself canceled proves the people working there don’t even try to protect patients but rather big pharma bottom line. If Prasad was so convinced the therapy doesn’t work then let ADCOM gather and you as regulator listen. No patient or their families would want anything be approved if it doesn’t work or could harm them so he could get prove he was right. Opposite was true hence cancelation $CAPR $SRPT $QURE gathered so much support that overwhelmed FDA and now to cover their useless asses they will keep scheduling ADCOMs right and left I hope they won’t invite saboteurs on purpose to not approve the therapy??? This agency is a waste of taxpayer money and should be abolished after what Makary&Prasad did?But if they can’t abolish FDA then what these clowns did will improve their work???
1 · Reply
Benalish
Benalish Jun. 26 at 5:47 PM
$OMER This stock gets pounded every week by Shorts, but one day, this stock is gonna rocket to $20 and never look back. Their drug is the best one and the science works. Regulators have been getting it wrong all year, just look at where $QURE and $REPL are now.
3 · Reply
stu4
stu4 Jun. 26 at 4:07 PM
$QURE W’hores left town! Matt gave them the skinny ahead Brokers taking care of brokers , fcuk the public
0 · Reply
aristocks
aristocks Jun. 26 at 3:51 PM
$QURE still looking for 76$ PT. Will re-evaluate if it goes below 46$. Took off some profit from my dip buying at 9$ - still bullish though.
1 · Reply
OMNIFALL
OMNIFALL Jun. 26 at 3:28 PM
$QURE the only problem with this company is *literally everyone* knows it doesnt work. still probably gets approved
0 · Reply
Latest News on QURE
uniQure price target raised to $80 from $50 at H.C. Wainwright

2026-06-29T10:00:16.000Z - 4 hours ago

uniQure price target raised to $80 from $50 at H.C. Wainwright

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Jun 25, 2026, 4:10 PM EDT - 3 days ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure price target raised to $68 from $35 at Mizuho

2026-06-25T11:26:12.000Z - 4 days ago

uniQure price target raised to $68 from $35 at Mizuho

uniQure 4.95M share Spot Secondary priced at $45.50

2026-06-24T01:51:45.000Z - 5 days ago

uniQure 4.95M share Spot Secondary priced at $45.50

uniQure Announces Pricing of Upsized $225 Million Public Offering

Jun 23, 2026, 9:13 PM EDT - 5 days ago

uniQure Announces Pricing of Upsized $225 Million Public Offering

UniQure Stock (QURE) Gains on Public Offering Plans

2026-06-23T18:40:00.000Z - 5 days ago

UniQure Stock (QURE) Gains on Public Offering Plans

uniQure rises 7.6%

2026-06-23T15:04:50.000Z - 5 days ago

uniQure rises 7.6%

uniQure announces $150M offering of common stock

2026-06-22T20:13:29.000Z - 6 days ago

uniQure announces $150M offering of common stock

uniQure Announces $150 Million Proposed Public Offering

Jun 22, 2026, 4:01 PM EDT - 6 days ago

uniQure Announces $150 Million Proposed Public Offering

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

2026-06-19T11:25:07.000Z - 10 days ago

uniQure reports preliminary data on first cohort in Phase I/IIa trial of AMT-260

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Jun 19, 2026, 7:05 AM EDT - 10 days ago

uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy

Barclays upgrades uniQure, calls BLA submission ‘major positive’

2026-06-18T12:22:32.000Z - 11 days ago

Barclays upgrades uniQure, calls BLA submission ‘major positive’

uniQure price target raised to $70 from $36 at Leerink

2026-06-18T11:31:03.000Z - 11 days ago

uniQure price target raised to $70 from $36 at Leerink

uniQure price target raised to $65 from $35 at RBC Capital

2026-06-18T11:18:09.000Z - 11 days ago

uniQure price target raised to $65 from $35 at RBC Capital

uniQure upgraded to Overweight from Equal Weight at Barclays

2026-06-18T11:12:32.000Z - 11 days ago

uniQure upgraded to Overweight from Equal Weight at Barclays

uniQure price target raised to $46 from $14 at Goldman Sachs

2026-06-18T10:27:49.000Z - 11 days ago

uniQure price target raised to $46 from $14 at Goldman Sachs

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

Jun 17, 2026, 12:12 PM EDT - 11 days ago

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

uniQure upgraded to Overweight at Cantor Fitzgerald after BLA filing news

2026-06-17T15:50:10.000Z - 11 days ago

uniQure upgraded to Overweight at Cantor Fitzgerald after BLA filing news

uniQure upgraded to Overweight from Neutral at Cantor Fitzgerald

2026-06-17T15:45:56.000Z - 11 days ago

uniQure upgraded to Overweight from Neutral at Cantor Fitzgerald

What made uniQure stock nearly double on Wednesday?

Jun 17, 2026, 11:32 AM EDT - 11 days ago

What made uniQure stock nearly double on Wednesday?

UniQure Stock (QURE) Rockets on an FDA Update

2026-06-17T14:56:04.000Z - 11 days ago

UniQure Stock (QURE) Rockets on an FDA Update

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

Jun 17, 2026, 10:10 AM EDT - 12 days ago

This Biotech Stock Is Surging 66% on Surprise Good News From FDA

uniQure AMT-130 update ‘materially positive,’ says H.C. Wainwright

2026-06-17T13:15:38.000Z - 12 days ago

uniQure AMT-130 update ‘materially positive,’ says H.C. Wainwright

UniQure gets FDA green light to file for Huntington's gene therapy approval

Jun 17, 2026, 7:13 AM EDT - 12 days ago

UniQure gets FDA green light to file for Huntington's gene therapy approval

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease

Jun 17, 2026, 7:05 AM EDT - 12 days ago

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease

uniQure Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 weeks ago

uniQure Earnings Call Transcript: Q1 2026

uniQure Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 weeks ago

uniQure Earnings release: Q1 2026

uniQure Quarterly report: Q1 2026

May 5, 2026, 8:30 AM EDT - 7 weeks ago

uniQure Quarterly report: Q1 2026

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

May 5, 2026, 7:05 AM EDT - 7 weeks ago

uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

Apr 30, 2026, 7:05 AM EDT - 2 months ago

uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington's Disease

uniQure to Announce First Quarter 2026 Financial Results

Apr 28, 2026, 7:05 AM EDT - 2 months ago

uniQure to Announce First Quarter 2026 Financial Results

uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

uniQure Proxy statement: Proxy filing

uniQure Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

uniQure Proxy statement: Proxy filing

uniQure Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 2 months ago

uniQure Proxy statement: Proxy filing

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Mar 9, 2026, 9:18 AM EDT - 4 months ago

This biotech's stock is soaring after a ‘polarizing' FDA official is stepping down

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

Mar 5, 2026, 6:01 PM EST - 4 months ago

Federal health officials attacked an Amsterdam-based biotech company seeking approval of a Huntington's disease treatment and accused it of lying

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Mar 5, 2026, 2:42 PM EST - 4 months ago

FDA official calls UniQure's gene therapy a 'failed' treatment for Huntington's disease

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

Mar 5, 2026, 1:11 PM EST - 4 months ago

Sr. FDA official calls Uniqure's Huntington's disease treatment a failure

FDA official says UniQure fell short on Huntington's trial, defends new study request

Mar 4, 2026, 11:01 PM EST - 4 months ago

FDA official says UniQure fell short on Huntington's trial, defends new study request

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 10:30 AM EST - 4 months ago

uniQure Transcript: TD Cowen 46th Annual Health Care Conference

uniQure Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:00 AM EST - 4 months ago

uniQure Earnings Call Transcript: Q4 2025

uniQure Earnings release: Q4 2025

Mar 2, 2026, 8:00 AM EST - 4 months ago

uniQure Earnings release: Q4 2025

uniQure Annual report: Q4 2025

Mar 2, 2026, 8:00 AM EST - 4 months ago

uniQure Annual report: Q4 2025

FDA tells UniQure study data insufficient for brain disorder therapy application

Mar 2, 2026, 7:22 AM EST - 4 months ago

FDA tells UniQure study data insufficient for brain disorder therapy application

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

Mar 2, 2026, 7:05 AM EST - 4 months ago

uniQure Announces 2025 Financial Results and Provides Recent Company Updates

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

Feb 25, 2026, 6:00 PM EST - 4 months ago

QURE INVESTOR REMINDER: uniQure N.V. Investors Have Until April 13, 2026 To Seek Lead Plaintiff Role

uniQure to Announce 2025 Financial Results

Feb 23, 2026, 7:05 AM EST - 4 months ago

uniQure to Announce 2025 Financial Results

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 18, 2026, 10:06 AM EST - 4 months ago

UniQure N.V. (QURE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

Feb 17, 2026, 8:16 AM EST - 4 months ago

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V.

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Feb 6, 2026, 7:05 AM EST - 5 months ago

uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

uniQure Slides: Corporate presentation

Jan 13, 2026, 7:00 AM EST - 5 months ago

uniQure Slides: Corporate presentation

uniQure Announces Type A Meeting Scheduled with FDA

Jan 9, 2026, 7:05 AM EST - 6 months ago

uniQure Announces Type A Meeting Scheduled with FDA

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Dec 7, 2025, 12:01 PM EST - 7 months ago

Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years

Thinkingman91
Thinkingman91 Jun. 29 at 2:00 PM
$CLPT $QURE $SRRK I’ve given you 3 since December and all went 50% or more. Im a chart specialist focusing on returns 🫡
1 · Reply
free2dream
free2dream Jun. 29 at 1:45 PM
$SPY LOAD UP ON $SRPT THE REAL SQUEEZE IS COMING 25% short float, pathetic 1.7B market cap while $QURE is at $3.3B . SAREPTA WIL GAP UP TO $60S easily
0 · Reply
free2dream
free2dream Jun. 29 at 1:36 PM
$SRPT ANALYST MORONS WAKE THE FXCK UP ! $QURE IS WORTH 2X SAREPTA ? YOU MUST BE JOKING
0 · Reply
victorgn
victorgn Jun. 29 at 1:15 PM
$QURE pops on open $52
0 · Reply
Benalish
Benalish Jun. 28 at 1:14 AM
$OMER Good time to be buying back conv debt. EU doesn’t like lack of placebo - just like $QURE in the USA. As I posted below, they have a better chance of approval with the appeal than they ever did with the initial due to the inclusion of real life experts who use Yart in the clinic. If I had known how this goes it would have been easy to anticipate. Good timing by $OMER to buy back conv during this manufactured pullback. Shorts knew it just like they knew $REPL was gonna get denied with Makary and Prasad at the FDA. Now $NVO heading back to $60 - they will probably consider cranking up the testing or maybe even a buyout at $20. Lots of biotech deals on the way with prices heating up !
1 · Reply
Evagaminska
Evagaminska Jun. 26 at 9:31 PM
$CAPR FDA still has clowns working there I guess if they schedule ADCOM but company isn’t aware. Prasad by issuing CRL without ADCOM that he himself canceled proves the people working there don’t even try to protect patients but rather big pharma bottom line. If Prasad was so convinced the therapy doesn’t work then let ADCOM gather and you as regulator listen. No patient or their families would want anything be approved if it doesn’t work or could harm them so he could get prove he was right. Opposite was true hence cancelation $CAPR $SRPT $QURE gathered so much support that overwhelmed FDA and now to cover their useless asses they will keep scheduling ADCOMs right and left I hope they won’t invite saboteurs on purpose to not approve the therapy??? This agency is a waste of taxpayer money and should be abolished after what Makary&Prasad did?But if they can’t abolish FDA then what these clowns did will improve their work???
1 · Reply
Benalish
Benalish Jun. 26 at 5:47 PM
$OMER This stock gets pounded every week by Shorts, but one day, this stock is gonna rocket to $20 and never look back. Their drug is the best one and the science works. Regulators have been getting it wrong all year, just look at where $QURE and $REPL are now.
3 · Reply
stu4
stu4 Jun. 26 at 4:07 PM
$QURE W’hores left town! Matt gave them the skinny ahead Brokers taking care of brokers , fcuk the public
0 · Reply
aristocks
aristocks Jun. 26 at 3:51 PM
$QURE still looking for 76$ PT. Will re-evaluate if it goes below 46$. Took off some profit from my dip buying at 9$ - still bullish though.
1 · Reply
OMNIFALL
OMNIFALL Jun. 26 at 3:28 PM
$QURE the only problem with this company is *literally everyone* knows it doesnt work. still probably gets approved
0 · Reply
OMNIFALL
OMNIFALL Jun. 26 at 3:16 PM
$CAPR i thought fraud was bullish now? it worked for $QURE , why not capr
0 · Reply
stu4
stu4 Jun. 26 at 1:47 PM
$QURE 100k shares , hoes
0 · Reply
stu4
stu4 Jun. 26 at 1:46 PM
$QURE and they flipped it
0 · Reply
Benalish
Benalish Jun. 26 at 1:41 PM
$OMER The same fight they had with the FDA, and that $REPL and $QURE have had with the FDA, is going to repeat again with the EU regulators. They are all cut from the same cloth.
0 · Reply
Benalish
Benalish Jun. 26 at 1:39 PM
$OMER It will go just like $QURE and $REPL - they will comment and pressure the EU to pass it similarly to how its happened at the FDA.
0 · Reply
free2dream
free2dream Jun. 26 at 1:39 PM
$SPY $SRPT THE SQUEEZE IN SAREPTA WILL BE ENORMOUS ! $1.8B market cap while $QURE is at $3B TOTAL NONSENSE
0 · Reply
Benalish
Benalish Jun. 26 at 1:32 PM
$OMER same issue as $QURE - I can’t believe we have to deal with fda in USA and cmhp in EU about not killing placebo patients
0 · Reply
OpenOutcrier
OpenOutcrier Jun. 26 at 12:52 PM
$QURE (-1.8% pre) uniQure closes $259 million public offering at $45.50 per share https://ooc.bz/l/106342
0 · Reply
Stef_Gee
Stef_Gee Jun. 26 at 12:40 PM
$QURE 🫡
1 · Reply
Dkll303
Dkll303 Jun. 26 at 11:17 AM
$QURE ouch
0 · Reply
stu4
stu4 Jun. 26 at 11:12 AM
$QURE leerink called this with buttboy behrens to be $35 and went to $13 the check for the write up didn’t bounce but the stock didn’t either
0 · Reply
stu4
stu4 Jun. 26 at 11:09 AM
$QURE take mizho over leerink they are mere hoes with a hedge partner
0 · Reply